Cstone Join Forces with SteinCares to Commercialize Sugemalimab in 10 Latin American Countries
Shots:
- CStone & SteinCares have partnered to commercialize sugemalimab, where SteinCares will gain its commercialization rights in 10 LATAM countries (incl. Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, & Ecuador), & CStone will handle its supply
- As per the terms, SteinCares will handle regulatory filings & marketing of sugemalimab in exchange for upfront, regulatory & commercial milestones as well as revenue from product supply
- Additionally, CStone is anticipating deals for sugemalimab in Western Europe, Southeast Asia & Canada, with regulatory submissions for new indications ongoing
Ref: CStone & SteinCares | Image: CStone & SteinCares
Related News:- CStone Pharmaceuticals’s Cejemly (Sugemalimab) Receives the EC’s Approval to Treat Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
